Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients

Second-generation tyrosine kinase inhibitors (2G-TKIs) dasatinib and nilotinib produced historical rates of about 50% complete cytogenetic response (CCyR) and about 40% major molecular response (MMR) in chronic myeloid leukaemia (CML) patients failing imatinib. Direct comparisons between dasatinib a...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Tiribelli, Mario, Bonifacio, Massimiliano, Binotto, Gianni, Iurlo, Alessandra, Cibien, Francesca, Maino, Elena, Guella, Anna, Festini, Gianluca, Minotto, Claudia, De Biasi, Ercole, De Marchi, Federico, Scaffidi, Luigi, Frison, Luca, Bucelli, Cristina, Medeot, Marta, Calistri, Elisabetta, Sancetta, Rosaria, Stulle, Manuela, Orofino, Nicola, Krampera, Mauro, Gherlinzoni, Filippo, Semenzato, Gianpietro, Pizzolo, Giovanni, Ambrosetti, Achille, Fanin, Renato
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5865665/
https://ncbi.nlm.nih.gov/pubmed/29581839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24478
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items